← Back to Clinical Trials
Recruiting NCT06558487

NCT06558487 The Internal Prospective Validation of the Cancer Admission Score (CAS) Prediction Model

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06558487
Status Recruiting
Phase
Sponsor Erasmus Medical Center
Condition Oncology
Study Type OBSERVATIONAL
Enrollment 200 participants
Start Date 2024-12-02
Primary Completion 2025-12-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
Cancer Admission Score Prediction Model

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 200 participants in total. It began in 2024-12-02 with a primary completion date of 2025-12-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this single center prospective observational study is to determine the agreement between the cancer admission score (CAS) predicted disposition and the actual disposition in patients with an active cancer diagnosis visiting the emergency department (ED). The main question it aims to answer are: Is the performance of the CAS good enough to play a potential role in the ED care process. For each participant the CAS will be calculated and compared to the actual outcome.

Eligibility Criteria

Inclusion Criteria: * Patients with solid or hematological malignancies and receiving systemic therapy or having received systemic therapy within the last 3 months. * Presented at or admitted from the emergency department for the oncology, hematology neuro- or lung-oncology clinical unit. Exclusion Criteria: * \<18 years old * Only received a surgical intervention as cancer treatment * Admitted to the ED for the surgical department

Contact & Investigator

Central Contact

Jason den Duijn

✉ j.denduijn@erasmusmc.nl

📞 0107040704

Principal Investigator

Jason den Duijn

PRINCIPAL INVESTIGATOR

Erasmus Medical Center

Frequently Asked Questions

Who can join the NCT06558487 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Oncology. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06558487 currently recruiting?

Yes, NCT06558487 is actively recruiting participants. Contact the research team at j.denduijn@erasmusmc.nl for enrollment information.

Where is the NCT06558487 trial being conducted?

This trial is being conducted at Rotterdam, Netherlands.

Who is sponsoring the NCT06558487 clinical trial?

NCT06558487 is sponsored by Erasmus Medical Center. The principal investigator is Jason den Duijn at Erasmus Medical Center. The trial plans to enroll 200 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology